corneal neovascularization
Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and bFGF-induced corneal neovascularization.
Experiments examining thalidomide's enantiomers reveal-that the S(-)-enantiomer has the strongest antiangiogenic activity in VEGF-induced and <span class="gene" id="9301478-4-142-146">bFGF</span>-induced <span class="disease" id="9301478-4-155-181">corneal neovascularization</span>.